Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis. Part I and Part II in healthy participants will be initiated prior to Part III in psoriasis participants. The primary hypotheses of the study are: 1) that MK-0873 is safe and well tolerated in healthy participants and participants with psoriasis and 2) that the maximum plasma concentration of MK-0873 is <20 nM in healthy participants and participants with psoriasis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: MK 0873

Criteria

Inclusion Criteria:

Part I, II and III:

• Female participants of reproductive potential must test negative for pregnancy and agree to use two acceptable methods of birth control;

• In good general health;

• Nonsmoker;

Part III only:

• Has diagnosis of plaque-type psoriasis, and has lesions covering at least 3% of total body surface area;

Exclusion Criteria:

Part I, II and III:

• Has a history of stroke, chronic seizures or major neurological disease;

• Has a history of cancer;

• Is a nursing mother;

Part III only:

• Has nonplaque forms of psoriasis;

• Has current drug-induced psoriasis;

• Has received phototherapy, systemic medications/treatments, or used topical medication that could affect psoriasis;

• Has used any systemic immunosuppressants or biologics within the past 4 weeks.